Active portfolio companies
|
7TM Pharma A/S is focused on discovery and development of new drugs targeting 7TM receptors. Its primary therapeutic area is metabolic diseases, including obesity, diabetes and cardiovascular diseases. 7TM is located in Copenhagen, Denmark. Novo A/S board representative: Søren Carlsen |
|||
|
|
|||
|
Alios BioPharma Inc. is developing novel treatments against viral diseases. Its lead programme is in pre-clinical development targeting HCV polymerase and is partnered with Vertex. Alios is located in California, USA. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
AlloCure Inc. is dedicated to developing adult stem cell therapies. Its most advanced compound is in phase 1 clinical development in the field of acute renal failure. AlloCure is located in Massachusetts and Utah, USA. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Altheos Inc. is a biotech company focused on the development of novel, small molecule drugs for the treatment of glaucoma. Its lead compound is in pre-clinical development. Altheos is located in California, USA. Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
AnaptysBio Inc. is an antibody therapeutics company and emerging leader in antibody discovery and optimisation. AnaptysBio is located in California, USA. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
Asante Solutions Inc. has developed an easy-to-use, disposable insulin pumps that are both affordable and reliable. The pump is 510(k) approved in the US and CE marked in Europe. The company is in pre-launch phase. Asante is located in California, USA. Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
BioMimetic Therapeutics Inc. is developing and commercialising drug device combination products for the repair of orthopaedic injuries to bone, cartilage, ligaments and tendons. BioMimetic is located in Tennessee, USA. Novo A/S board representative: Thorkil Kastberg Christensen |
|||
|
|
|||
|
Biotie Therapies Corporation is focused on the development of drugs for neurodegenerative and psychiatric disorders. Biotie is located in Turku, Finland. |
|||
|
|
|||
|
Cianna Medical Inc. is a medical device company dedicated to the innovative treatment of early-stage breast cancer. The company manufactures and markets the SAVI breast brachytherapy applicator, for the delivery of radiation after lumpectomy surgery. Cianna is located in California, USA. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
Delenex Therapeutics AG is developing therapeutic antibody fragments targeting serious medical diseases with unmet need. These antibody fragments are being designed for local/topical application. Delenex is located in Zürich, Switzerland. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Elevation Pharmaceuticals Inc. Elevation Pharmaceuticals Inc. develops new inhaled therapies for patients with respiratory disease. Its lead drug candidate is in phase 2 clinical development for the improved treatment of patients with COPD. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
f-star GmbH is developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology. Its lead compound is in pre-clinical development. f-star is located in Cambridgeshire, UK and Vienna, Austria. Novo A/S board representative: Kim L. Dueholm |
|||
|
|
|||
|
FLAPCo, LLC FLAPCo, LLC is a non-operational entity that was set up after the acquisition of Amira by Bristol-Myers Squibb Inc. FLAPCo holds the rights to the FLAP antagonists licensed to GlaxoSmithKline by Amira Pharmaceuticals Inc. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
Funxional Therapeutics Ltd. is developing a first in class, broad spectrum anti-inflammatory compound which is currently in phase 2 trials. Funxional is located in Cambridgeshire, UK. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
HTG Molecular Diagnostics, Inc. HTG Molecular Diagnostics Inc. develops and sells assays for quantification of gene expression. The assays are used for clinical diagnostics, as well as in academic and pharmaceutical research. The techonology has special advantages when used on formalin fixed paraffin embedded tissue samples. HTG is located in Arizona, USA. Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
Imagen Biotech, Inc. aims to identify and develop treatments for blinding diseases with high unmet medical needs. They focus particularly on dry Age-related Macular Degeneration. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Inogen Inc. is developing, manufacturing and marketing lightweight, portable oxygen therapy devices to improve quality of life and increase mobility for patients with Chronic Obstructive Pulmonary Disease. Inogen is located in California, USA. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
KalVista Pharmaceuticals Ltd. is developing plasma kallikrein inhibitors for the treatment of diabetic macular oedema. KalVista is located in Hampshire, UK. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Light Sciences Oncology Inc. is in late-stage development of Aptocine™, a drug activated by a disposable drug activator, for the treatment of solid tumours as well as other indications. The product is in phase 3 trials for hepatoma cancer and colon cancer. Light Sciences Oncology is located in Washington, USA. Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
Lux Biosciences Inc. is dedicated to the development and commercialisation of pharmaceutical products for the treatment of ophthalmic diseases. Lux is located in New Jersey, USA. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Metabolex Inc. is discovering and developing novel therapeutics to treat diabetes and related metabolic disorders. Its lead programmes are in phase 2 clinical development. Metabolex is located in California, USA. |
|||
|
|
|||
|
NeoMend Inc. develops products that facilitate sealing and healing of soft tissue wounds. NeoMend’s ProGEL™ Lung Surgery Device was approved by the FDA in 2010. NeoMend is located in California, USA. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
NeuroTherapeutics Pharma, Inc. NeuroTherapeutics Pharma Inc. is focused on developing novel small molecule therapeutics for diseases associated with CNS hyperexcitability, including epilepsy and pain. Its lead candidate is in pre-clinical development. NeuroTherapeutics is located in Illinois, USA. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
Ophthotech Corporation is focused on developing improved therapies for dry and wet Age-related Macular Degeneration. Its lead compound is in phase 2 clinical development. Ophthotech is located in New Jersey, USA. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Orphazyme develops novel therapeutic strategy for the treatment of lysosomal storage diseases. Orphazyme is located in Copenhagen, Denmark. Novo A/S board representatives: Kim L. Dueholm and Peter Moldt |
|||
|
|
|||
|
Otonomy Inc. is developing novel drug therapies for disorders of the inner and middle ear. Its lead candidate is ready to enter phase 2 clinical development for the treatment of Ménière’s disease. Otonomy is located in California, USA. Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
Panmira Pharmaceuticals, LLC was created after the acquisition of Amira Pharmaceuticals Inc. by Bristol-Myers Squibb Inc. Panmira holds a number of anti-inflammatory assets that were spun out of Amira, and the company seeks to partner these programmes. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
ProteinSimple Inc. is developing instrumentation systems, software and assay products that drive discoveries in fields ranging from fundamental protein research to biomarker discovery and personalised medicine. ProteinSimple is located in California, USA. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
PTC Therapeutics Inc. discovers and develops small molecule drugs that modulate gene expression by selectively binding to RNA targets. PTC is located in New Jersey, USA. Novo A/S board representative: Søren Carlsen |
|||
|
|
|||
|
Reata Pharmaceuticals Inc. is developing new drugs for the treatment of kidney disease and inflammatory diseases. Its lead programme is in late-stage clinical development for Chronic Kidney Disease. Reata is located in Texas, USA. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
Santaris Pharma A/S is in clinical development of RNA antagonist drugs against metabolic disorders and viral disease. The technology is also being developed for products targeting micro-RNA. Santaris is located in Copenhagen, Denmark. Novo A/S board representative: Søren Carlsen |
|||
|
|
|||
|
Symphogen A/S is developing recombinant human polyclonal and oligoclonal antibodies. The focus of the company is on antibody combinations for cancer treatment. Symphogen is located in Copenhagen, Denmark. |
|||
|
|
|||
|
Tarsa Therapeutics Inc. developing an oral calcitonin for the treatment of osterporosis. Positive phase 3 data has been announced and the NDA is in preparation. Tarsa is located in Pennsylvania, USA. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Tobira Therapeutics Inc. develops products for the treatment of viral diseases. The lead compound, a CCR5 antagonist for the treatment of HIV infection, is in a phase 2B study. Tobira is located in New Jersey, USA. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
Vantia Therapeutics Ltd. is developing small molecule agonists and antagonists of vasopressin receptors. Its lead assets are in phase 2 trials for the treatment of nocturia and dysmenorrhea. Vantia is located in Hampshire, UK. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Veloxis Pharmaceuticals A/S has a new and impreoved once-daily tacrolimus product in late-stage clinical development based on a novel drug delivery platform. Veloxis is located in Copenhagen, Denmark and New Jersey, USA. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Xenon Pharmaceuticals Inc. is a genetics-based drug development company, discovering innovative drugs. Its lead compound is in clinical studies for the treatment of pain. Xenon is located in British Columbia, Canada. |
|||
|
|
|||